ArticleMethods (San Diego, Calif.)2014
Recombinant house dust mite allergens.
Article in Methods (San Diego, Calif.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial.International archives of allergy and immunology · 2019Trial
- Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children.The Journal of allergy and clinical immunology · 2015Trial
- Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- The adeno associated viral vectored Dp12S vaccine effective alleviation of asthma symptoms in mice.NPJ vaccines · 2025Article
- From skin testing to molecular diagnostics: the precision leap in dust mite allergy diagnosis and clinical translation challenges.Frontiers in allergy · 2025Review
- Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model.Immunity, inflammation and disease · 2023Article
- Degradation of bacterial permeability family member A1 (BPIFA1) by house dust mite (HDM) cysteine protease Der p 1 abrogates immune modulator function.International journal of biological macromolecules · 2020Article
- Mite allergy and atopic dermatitis: Is there a clear link? (Review).Experimental and therapeutic medicine · 2020Review
- Effects of Ser47-Point Mutation on Conformation Structure and Allergenicity of the Allergen of Der p 2, a Major House Dust Mite Allergen.Allergy, asthma & immunology research · 2019Article
- Homology modeling and epitope prediction of Der f 33.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- Allergens with Protease Activity from House Dust Mites.International journal of molecular sciences · 2017Review
- Natural Evolution of IgE Responses to Mite Allergens and Relationship to Progression of Allergic Disease: a Review.Current allergy and asthma reports · 2017Review
- House Dust Mite Allergens: New Discoveries and Relevance to the Allergic Patient.Current allergy and asthma reports · 2016Review
- Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen.PloS one · 2016Article
- Effect of Amino Acid Polymorphisms of House Dust Mite Der p 2 Variants on Allergic Sensitization.Allergy, asthma & immunology research · 2016Article
- Characterization of a new subtype of allergen in dermatophagoides farinae-Der f 28.Journal of thoracic disease · 2015Article
- Expression, purification and characterization of Der f 27, a new allergen from dermatophagoides farinae.American journal of translational research · 2015Article
- Characterization of Der f 29, a new allergen from dermatophagoides farinae.American journal of translational research · 2015Article
- Immunotherapy for house dust mite sensitivity: where are the knowledge gaps?Current allergy and asthma reports · 2014Review
- Expression, cloning, and IgE-binding of the full-length dust mite allergen Der f 8.Immunologic research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
House dust mites (HDM) are a globally important source of allergen responsible for the sensitization of more than 50% of allergic patients. Specific immunotherapy with HDM extracts is effective but allergen extracts cannot be fully standardized and severe side-effects can occur during the protracted course of treatment. The introduction of molecular biological techniques into allergy research allowed the indentification of more than 20 groups of HDM allergens. Recombinant HDM allergens can be produced in defined concentrations and consistent quality and allow the development of vaccines for HDM allergy with reduced allergenic activity and retained immunogenicity. The immunotherapy trials in pollen allergic patients with recombinant pollen allergens/hypoallergenic allergen derivatives have shown that this treatment is effective and indicated that recombinant HDM vaccines might improve immunotherapy of HDM allergic patients. Here we report the steps for the development of vaccines for HDM allergy. After selection of the most prevalent HDM species, the panel of allergens to be included into a therapeutic vaccine for HDM allergy needs to be determined. HDM allergens with high IgE-binding frequency and clinical relevance will be modified into hypoallergenic variants and evaluated for their allergenic activity and immunogenicity. Derivatives with reduced allergenic activity but with retained immunogenicity would be good candidates for a HDM vaccine for safe and efficient immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.